Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression
Mark J. Niciu, Bridget Shovestul, Brittany A. Jaso, et al.
Journal of Affective Disorders (2018) Vol. 232, pp. 310-315
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
Roger S. McIntyre, Joshua D. Rosenblat, Charles B. Nemeroff, et al.
American Journal of Psychiatry (2021) Vol. 178, Iss. 5, pp. 383-399
Open Access | Times Cited: 468
Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial
Jennifer L. Phillips, Sandhaya Norris, Jeanne Talbot, et al.
American Journal of Psychiatry (2019) Vol. 176, Iss. 5, pp. 401-409
Open Access | Times Cited: 337
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine
Danilo De Gregorio, Argel Aguilar‐Valles, Katrin H. Preller, et al.
Journal of Neuroscience (2020) Vol. 41, Iss. 5, pp. 891-900
Open Access | Times Cited: 185
Long-term safety of ketamine and esketamine in treatment of depression
Sina Nikayin, Eva Murphy, John H. Krystal, et al.
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 777-787
Closed Access | Times Cited: 69
Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?
Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience (2024)
Open Access | Times Cited: 28
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms
Samuel Kohtala
Pharmacological Reports (2021) Vol. 73, Iss. 2, pp. 323-345
Open Access | Times Cited: 92
Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports
Charlotte Martial, Héléna Cassol, Vanessa Charland‐Verville, et al.
Consciousness and Cognition (2019) Vol. 69, pp. 52-69
Open Access | Times Cited: 82
A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression
Paulo Shiroma, Paul Thuras, Joseph Wels, et al.
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 77
Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments
Kyle T. Greenway, Nicolas Garel, Lisa Jerome, et al.
Expert Review of Clinical Pharmacology (2020) Vol. 13, Iss. 6, pp. 655-670
Closed Access | Times Cited: 72
Ketamine and its metabolites: Potential as novel treatments for depression
Kai Zhang, Yitan Yao, Kenji Hashimoto
Neuropharmacology (2022) Vol. 222, pp. 109305-109305
Closed Access | Times Cited: 59
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
Guang Chen, Li Chen, Yun Zhang, et al.
The International Journal of Neuropsychopharmacology (2022) Vol. 25, Iss. 4, pp. 269-279
Open Access | Times Cited: 42
Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine
David S. Mathai, Sandeep M. Nayak, David B. Yaden, et al.
Psychopharmacology (2023) Vol. 240, Iss. 4, pp. 827-836
Closed Access | Times Cited: 30
The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research
Meysam Amidfar, Marie Woelfer, Gislaine Z. Réus, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2019) Vol. 94, pp. 109668-109668
Closed Access | Times Cited: 75
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial
Thomas D. Hull, Matteo Malgaroli, Adam Gazzaley, et al.
Journal of Affective Disorders (2022) Vol. 314, pp. 59-67
Open Access | Times Cited: 35
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin, et al.
Psychopharmacology (2023) Vol. 240, Iss. 7, pp. 1547-1560
Open Access | Times Cited: 18
Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder
Sabine Aust, Matti Gärtner, Laura Basso, et al.
European Neuropsychopharmacology (2019) Vol. 29, Iss. 4, pp. 529-538
Closed Access | Times Cited: 50
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence
Nelson B. Rodrigues, Roger S. McIntyre, Orly Lipsitz, et al.
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 8, pp. 1031-1040
Closed Access | Times Cited: 40
The effect of sexual abuse and dissociation on suicide attempt
Silje Støle Brokke, Thomas Bjerregaard Bertelsen, Nils Inge Landrø, et al.
BMC Psychiatry (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 22
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression
Alice Lineham, Victor J. Avila‐Quintero, Michael H. Bloch, et al.
Journal of Child and Adolescent Psychopharmacology (2023) Vol. 33, Iss. 1, pp. 20-26
Closed Access | Times Cited: 15
Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach
Phil Wolfson, Gita Vaid
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 5
Experiences of Awe Mediate Ketamine’s Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression
Julia Aepfelbacher, Benjamin Panny, Rebecca B. Price
Biological Psychiatry Global Open Science (2024) Vol. 4, Iss. 4, pp. 100316-100316
Open Access | Times Cited: 5
How-To Study Dissociative Symptoms in a Broad Range of Mental Disorders: A Methodological Primer
Sarah K. Danböck, Yoki L. Mertens, Patricia Kulla, et al.
Journal of Trauma & Dissociation (2025), pp. 1-37
Open Access
Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways
Ji‐Woon Kim, Lisa M. Monteggia
Behavioural Brain Research (2019) Vol. 380, pp. 112378-112378
Open Access | Times Cited: 41
Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review
Meryem Grabski, Anna Borissova, Beth Marsh, et al.
Behavioural Brain Research (2020) Vol. 392, pp. 112629-112629
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top